{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:03Z","timestamp":1794047523679,"version":"4.8.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T00:00:00Z","timestamp":1503878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,21]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs), both non-selective and selective cyclooxygenase-2 (COX-2) inhibitors, are among the most widely prescribed drugs worldwide, but associate with increased blood pressure (BP) and adverse cardiovascular (CV) events. PRECISION-ABPM, a substudy of PRECISION was conducted at 60 sites, to determine BP effects of the selective COX-2 inhibitor celecoxib vs. the non-selective NSAIDs naproxen and ibuprofen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62\u2009\u00b1\u200910\u2009years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100\u2013200\u2009mg bid), ibuprofen (600\u2013800\u2009mg tid), or naproxen (375\u2013500\u2009mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4\u2009months. The change in mean 24-h systolic BP (SBP) in celecoxib, ibuprofen and naproxen-treated patients was -0.3\u2009mmHg [95% confidence interval (CI), \u22122.25, 1.74], 3.7 (95% CI, 1.72, 5.58) and 1.6\u2009mmHg (95% CI, \u22120.40, 3.57), respectively. These changes resulted in a difference of\u2009\u2212\u20093.9\u2009mmHg (P\u2009=\u20090.0009) between celecoxib and ibuprofen, of\u2009\u2212\u20091.8\u2009mmHg (P\u2009=\u20090.12) between celecoxib and naproxen, and of\u2009\u2212\u20092.1\u2009mmHg (P\u2009=\u20090.08) between naproxen and ibuprofen. The percentage of patients with normal baseline BP who developed hypertension (mean 24-h SBP\u2009\u2265\u2009130 and\/or diastolic BP\u2009\u2265\u200980\u2009mmHg) was 23.2% for ibuprofen, 19.0% for naproxen, and 10.3% for celecoxib (odds ratio 0.39, P\u2009=\u20090.004 and odds ratio 0.49, P\u2009=\u20090.03 vs. ibuprofen and naproxen, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In PRECISION-ABPM, allocation to the non-selective NSAID ibuprofen, compared with the COX-2 selective inhibitor celecoxib was associated with a significant increase of SBP, and a higher incidence of new-onset hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials<\/jats:title>\n                  <jats:p>gov number NCT00346216<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehx508","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T19:13:14Z","timestamp":1503342794000},"page":"3282-3292","source":"Crossref","is-referenced-by-count":116,"title":["Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial"],"prefix":"10.1093","volume":"38","author":[{"given":"Frank","family":"Ruschitzka","sequence":"first","affiliation":[{"name":"Cardiology, University Heart Center, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Borer","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Schiavone Cardiovascular Translational Research Institute, State University of New York, Downstate College of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J","family":"Flammer","sequence":"additional","affiliation":[{"name":"Cardiology, University Heart Center, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville D","family":"Yeomans","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Western Sydney University, Campbelltown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"Cardiology, University Heart Center, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Elaine","family":"Husni","sequence":"additional","affiliation":[{"name":"Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y","family":"Graham","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A","family":"Davey","sequence":"additional","affiliation":[{"name":"Department for Cleveland Clinic, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Department for Cleveland Clinic, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Menon","sequence":"additional","affiliation":[{"name":"Department for Cleveland Clinic, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Fayyad","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Pfizer, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Beckerman","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Pfizer, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu","family":"Iorga","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Pfizer, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Nissen","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"2021031608395951500_ehx508-B1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamainternmed.2015.0809","article-title":"Nonsteroidal anti-inflammatory drug use in a patient with hypertension: a teachable moment","volume":"175","author":"Kumar","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2021031608395951500_ehx508-B2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archinte.167.4.394","article-title":"Frequency of analgesic use and risk of hypertension among men","volume":"167","author":"Forman","year":"2007","journal-title":"Arch Intern Med"},{"key":"2021031608395951500_ehx508-B3","first-page":"1843","article-title":"Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the standard care vs. celecoxib outcome trial (SCOT)","volume":"38","author":"MacDonald","year":"2017","journal-title":"Eur Heart J"},{"key":"2021031608395951500_ehx508-B4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","article-title":"Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States","volume":"41","author":"Lawrence","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2021031608395951500_ehx508-B5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0149-2918(03)90017-8","article-title":"The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care","volume":"25","author":"Harley","year":"2003","journal-title":"Clin Ther"},{"key":"2021031608395951500_ehx508-B6","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1016\/0002-9343(91)90485-G","article-title":"Nonsteroidal anti-inflammatory drugs and antihypertensives","volume":"90","author":"Houston","year":"1991","journal-title":"Am J Med"},{"key":"2021031608395951500_ehx508-B7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"2021031608395951500_ehx508-B8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(08)60137-3","article-title":"COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs","volume":"371","author":"Warner","year":"2008","journal-title":"Lancet"},{"key":"2021031608395951500_ehx508-B9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann Intern Med"},{"key":"2021031608395951500_ehx508-B10","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"key":"2021031608395951500_ehx508-B11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"2021031608395951500_ehx508-B12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"key":"2021031608395951500_ehx508-B13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.1994.03520100043031","article-title":"Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy","volume":"272","author":"Gurwitz","year":"1994","journal-title":"JAMA"},{"key":"2021031608395951500_ehx508-B14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"2021031608395951500_ehx508-B15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","article-title":"Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis","volume":"157","author":"Becker","year":"2009","journal-title":"Am Heart J"},{"key":"2021031608395951500_ehx508-B16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021031608395951500_ehx508-B17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"2021031608395951500_ehx508-B18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","article-title":"Coxibs and cardiovascular disease","volume":"351","author":"Fitzgerald","year":"2004","journal-title":"N Engl J Med"},{"key":"2021031608395951500_ehx508-B19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/01.HYP.0000149684.01903.b8","article-title":"Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?","volume":"45","author":"Grover","year":"2005","journal-title":"Hypertension"},{"key":"2021031608395951500_ehx508-B20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch Intern Med"},{"key":"2021031608395951500_ehx508-B21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/01.HYP.0000115921.55353.e0","article-title":"Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics","volume":"43","author":"Izhar","year":"2004","journal-title":"Hypertension"},{"key":"2021031608395951500_ehx508-B22","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/HJH.0b013e328302c9fe","article-title":"Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial","volume":"26","author":"MacDonald","year":"2008","journal-title":"J Hypertens"},{"key":"2021031608395951500_ehx508-B23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0895-7061(00)01204-8","article-title":"Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril","volume":"13","author":"Morgan","year":"2000","journal-title":"Am J Hypertens"},{"key":"2021031608395951500_ehx508-B24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/00004872-199508000-00014","article-title":"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients","volume":"13","author":"Polonia","year":"1995","journal-title":"J Hypertens"},{"key":"2021031608395951500_ehx508-B25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1177\/0091270007307878","article-title":"Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet","volume":"47","author":"Schwartz","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2021031608395951500_ehx508-B26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","article-title":"The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-h blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus","volume":"165","author":"Sowers","year":"2005","journal-title":"Arch Intern Med"},{"key":"2021031608395951500_ehx508-B27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.0000014323.99765.16","article-title":"Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors","volume":"39","author":"White","year":"2002","journal-title":"Hypertension"},{"key":"2021031608395951500_ehx508-B28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"2021031608395951500_ehx508-B29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"2021031608395951500_ehx508-B30","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"2021031608395951500_ehx508-B31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"2021031608395951500_ehx508-B32","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.106.636746","article-title":"Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas","volume":"114","author":"Solomon","year":"2006","journal-title":"Circulation"},{"key":"2021031608395951500_ehx508-B33","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N Engl J Med"},{"key":"2021031608395951500_ehx508-B34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2004.10.001","article-title":"Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs","volume":"177","author":"Walter","year":"2004","journal-title":"Atherosclerosis"},{"key":"2021031608395951500_ehx508-B35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.HYP.0000084603.93510.28","article-title":"Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension","volume":"42","author":"Widlansky","year":"2003","journal-title":"Hypertension"},{"key":"2021031608395951500_ehx508-B36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/01.CIR.0000051361.69808.3A","article-title":"Selective COX-2 inhibition improves endothelial function in coronary artery disease","volume":"107","author":"Chenevard","year":"2003","journal-title":"Circulation"},{"key":"2021031608395951500_ehx508-B37","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1161\/01.CIR.0000160358.63804.C9","article-title":"Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation","volume":"111","author":"Steffel","year":"2005","journal-title":"Circulation"},{"key":"2021031608395951500_ehx508-B38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"2021031608395951500_ehx508-B39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/CIRCULATIONAHA.110.984054","article-title":"Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed?","volume":"122","author":"White","year":"2010","journal-title":"Circulation"},{"key":"2021031608395951500_ehx508-B40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2125.1990.tb03640.x","article-title":"Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man","volume":"29","author":"Bippi","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"2021031608395951500_ehx508-B41","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.110.956490","article-title":"Acetaminophen increases blood pressure in patients with coronary artery disease","volume":"122","author":"Sudano","year":"2010","journal-title":"Circulation"},{"key":"2021031608395951500_ehx508-B42","doi-asserted-by":"crossref","first-page":"j1909.","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"2021031608395951500_ehx508-B43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jama.282.6.539","article-title":"Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators","volume":"282","author":"Staessen","year":"1999","journal-title":"JAMA"},{"key":"2021031608395951500_ehx508-B44","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/HJH.0b013e328363e964","article-title":"European Society of Hypertension Working Group on Blood Pressure M. European Society of Hypertension position paper on ambulatory blood pressure monitoring","volume":"31","author":"O'Brien","year":"2013","journal-title":"J Hypertens"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/44\/3282\/36614558\/ehx508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/44\/3282\/36614558\/ehx508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T09:38:07Z","timestamp":1615887487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/44\/3282\/4096359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":44,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2017,8,28]]},"published-print":{"date-parts":[[2017,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx508","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,8,28]]}}}